<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32216828</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2051-5960</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>26</Day></PubDate></JournalIssue><Title>Acta neuropathologica communications</Title><ISOAbbreviation>Acta Neuropathol Commun</ISOAbbreviation></Journal><ArticleTitle>Neuropathological correlates of parkinsonian disorders in a large Dutch autopsy series.</ArticleTitle><Pagination><StartPage>39</StartPage><MedlinePgn>39</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">39</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40478-020-00914-9</ELocationID><Abstract><AbstractText>The clinical diagnosis in patients with parkinsonian disorders can be challenging, and a definite diagnosis requires neuropathological confirmation. The aim of this study was to examine whether a clinical diagnosis of Parkinson's disease (PD) and atypical parkinsonian disorders predict the presence of Lewy pathology (LP) and concomitant neuropathological lesions.We included 293 donors with a history of parkinsonism without dementia at disease onset, collected by the Netherlands Brain Bank (NBB)&#xa0;from 1989 to 2015. We retrospectively categorized donors according the International Parkinson and Movement Disorder Society clinical diagnostic criteria for PD (MDS-PD criteria) as 'not PD', 'probable PD' or 'established PD'. We compared the final clinical diagnosis to presence of neuropathological lesions as defined by BrainNet Europe and National&#xa0;Institute on&#xa0;Aging&#xa0;- Alzheimer's Association guidelines.LP was present in 150 out of 176 donors (85%) with a clinical diagnosis of PD, in 8 out of 101 donors (8%) with atypical parkinsonian disorders and in 4 out of 16 donors (25%) without a definite clinical diagnosis. Independent from age at death, stages of amyloid-&#x3b2;, but not neurofibrillary tau or neuritic plaques, were higher in donors with LP compared to other types of pathology (p&#x2009;=&#x2009;0.009). The MDS-PD criteria at a certainty level of 'probable PD' predicted presence of LP with a diagnostic accuracy of 89.3%. Among donors with LP, 'established PD' donors showed similar Braak &#x3b1;-synuclein stages and stages of amyloid-&#x3b2;, neurofibrillary tau and neuritic plaques compared to 'not PD' or 'probable PD' donors.In conclusion, both a clinical diagnosis of PD as well as MDS-PD criteria accurately predicted presence of LP in NBB donors. LP was associated with more widespread amyloid-&#x3b2; pathology, suggesting a link between amyloid-&#x3b2; accumulation and LP formation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Geut</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Neurosciences, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, P.O. Box 7057, 1007, MB, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Netherlands Brain Bank, Netherlands Institute for Neuroscience, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hepp</LastName><ForeName>D H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foncke</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berendse</LastName><ForeName>H W</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rozemuller</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Pathology, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huitinga</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Netherlands Brain Bank, Netherlands Institute for Neuroscience, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Berg</LastName><ForeName>W D J</ForeName><Initials>WDJ</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Neurosciences, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, P.O. Box 7057, 1007, MB, Amsterdam, the Netherlands. wdj.vandeberg@amsterdamumc.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Acta Neuropathol Commun</MedlineTA><NlmUniqueID>101610673</NlmUniqueID><ISSNLinking>2051-5960</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019578" MajorTopicYN="N">Multiple System Atrophy</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013494" MajorTopicYN="N">Supranuclear Palsy, Progressive</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyloid-&#x3b2;</Keyword><Keyword MajorTopicYN="N">Lewy pathology</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32216828</ArticleId><ArticleId IdType="pmc">PMC7098103</ArticleId><ArticleId IdType="doi">10.1186/s40478-020-00914-9</ArticleId><ArticleId IdType="pii">10.1186/s40478-020-00914-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol. 2006;5:75&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">16361025</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler CH, Beach TG, Hentz JG, Shill HA, Caviness JN, Driver-Dunckley E, Sabbagh MN, Sue LI, Jacobson SA, Belden CM, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology. 2014;83:406&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4132570</ArticleId><ArticleId IdType="pubmed">24975862</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath J, Burkhard PR, Bouras C, Kovari E. Etiologies of parkinsonism in a century-long autopsy-based cohort. Brain Pathol. 2013;23:28&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">22702335</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol. 1993;50:140&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">8431132</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology. 2001;57:1497&#x2013;1499.</Citation><ArticleIdList><ArticleId IdType="pubmed">11673599</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA (2007) Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study. J Neural Transm Suppl:91&#x2013;104</Citation><ArticleIdList><ArticleId IdType="pubmed">17982882</ArticleId></ArticleIdList></Reference><Reference><Citation>Joutsa J, Gardberg M, Roytta M, Kaasinen V. Diagnostic accuracy of parkinsonism syndromes by general neurologists. Parkinsonism Relat Disord. 2014;20:840&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">24816002</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology. 2016;86:566&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pubmed">26764028</ArticleId></ArticleIdList></Reference><Reference><Citation>Bower JH, Dickson DW, Taylor L, Maraganore DM, Rocca WA. Clinical correlates of the pathology underlying parkinsonism: a population perspective. Mov Disord. 2002;17:910&#x2013;916.</Citation><ArticleIdList><ArticleId IdType="pubmed">12360539</ArticleId></ArticleIdList></Reference><Reference><Citation>Turcano P, Mielke MM, Josephs KA, Bower JH, Parisi JE, Boeve BF, Savica R (2017) Clinicopathologic discrepancies in a population-based incidence study of parkinsonism in olmsted county: 1991-2010. Mov Disord. 10.1002/mds.27125</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5931206</ArticleId><ArticleId IdType="pubmed">28843020</ArticleId></ArticleIdList></Reference><Reference><Citation>Fereshtehnejad SM, Zeighami Y, Dagher A, Postuma RB. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression. Brain. 2017;140:1959&#x2013;1976.</Citation><ArticleIdList><ArticleId IdType="pubmed">28549077</ArticleId></ArticleIdList></Reference><Reference><Citation>Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A clinico-pathological study of subtypes in Parkinson's disease. Brain. 2009;132:2947&#x2013;2957.</Citation><ArticleIdList><ArticleId IdType="pubmed">19759203</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschbichler ST, Erro R, Ganos C, Stamelou M, Batla A, Balint B, Bhatia KP. "Atypical" atypical parkinsonism: critical appraisal of a cohort. Parkinsonism Relat Disord. 2017;37:36&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">28236526</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA, Attems J (2015) Challenges of multimorbidity of the aging brain: a critical update. Journal of neural transmission (Vienna, Austria : 1996) 122: 505-521 Doi 10.1007/s00702-014-1288-x</Citation><ArticleIdList><ArticleId IdType="pubmed">25091618</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Lee EB, Xie SX, Rennert L, Suh E, Bredenberg C, Caswell C, Van Deerlin VM, Yan N, Yousef A, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018;141:2181&#x2013;2193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6022546</ArticleId><ArticleId IdType="pubmed">29878075</ArticleId></ArticleIdList></Reference><Reference><Citation>Compta Y, Parkkinen L, Kempster P, Selikhova M, Lashley T, Holton JL, Lees AJ, Revesz T. The significance of alpha-synuclein, amyloid-beta and tau pathologies in Parkinson's disease progression and related dementia. Neurodegener Dis. 2014;13:154&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4194631</ArticleId><ArticleId IdType="pubmed">24028925</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, Lee VM, Leverenz JB, Montine TJ, Duda JE, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol. 2012;72:587&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3484250</ArticleId><ArticleId IdType="pubmed">23037886</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepp DH, Vergoossen DL, Huisman E, Lemstra AW, Berendse HW, Rozemuller AJ, Foncke EM, van de Berg WD. Distribution and load of amyloid-beta pathology in Parkinson disease and dementia with Lewy bodies. J Neuropathol Exp Neurol. 2016;75:936&#x2013;945.</Citation><ArticleIdList><ArticleId IdType="pubmed">27516115</ArticleId></ArticleIdList></Reference><Reference><Citation>Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30:1591&#x2013;1601.</Citation><ArticleIdList><ArticleId IdType="pubmed">26474316</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology. 2005;65:1863&#x2013;1872.</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Del Tredici K, Wszolek ZK, et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol. 2009;8:1150&#x2013;1157.</Citation><ArticleIdList><ArticleId IdType="pubmed">19909913</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Durr A, Fowler CJ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676993</ArticleId><ArticleId IdType="pubmed">18725592</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8710059</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012;123:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs GG, Ghetti B, Halliday G, Holm IE, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010;119:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2799633</ArticleId><ArticleId IdType="pubmed">19924424</ArticleId></ArticleIdList></Reference><Reference><Citation>Alafuzoff I, Ince PG, Arzberger T, Al-Sarraj S, Bell J, Bodi I, Bogdanovic N, Bugiani O, Ferrer I, Gelpi E, et al. Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe consortium. Acta Neuropathol. 2009;117:635&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pubmed">19330340</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1014720</ArticleId><ArticleId IdType="pubmed">1564476</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology. 1992;42:1142&#x2013;1146.</Citation><ArticleIdList><ArticleId IdType="pubmed">1603339</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori H, Oda M, Komori T, Arai N, Takanashi M, Mizutani T, Hirai S, Mizuno Y. Lewy bodies in progressive supranuclear palsy. Acta Neuropathol. 2002;104:273&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">12172913</ArticleId></ArticleIdList></Reference><Reference><Citation>Cykowski MD, Coon EA, Powell SZ, Jenkins SM, Benarroch EE, Low PA, Schmeichel AM, Parisi JE. Expanding the spectrum of neuronal pathology in multiple system atrophy. Brain. 2015;138:2293&#x2013;2309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4840945</ArticleId><ArticleId IdType="pubmed">25981961</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Rub U, Del Tredici K. Involvement of precerebellar nuclei in multiple system atrophy. Neuropathol Appl Neurobiol. 2003;29:60&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">12581341</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozawa T (2004) The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 127(12):2657&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">15509623</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA. More frequent Lewy bodies but less frequent Alzheimer-type lesions in multiple system atrophy as compared to age-matched control brains. Acta Neuropathol. 2007;114:299&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">17476513</ArticleId></ArticleIdList></Reference><Reference><Citation>Swirski M, Miners JS, de Silva R, Lashley T, Ling H, Holton J, Revesz T, Love S. Evaluating the relationship between amyloid-beta and alpha-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson's disease. Alzheimers Res Ther. 2014;6:77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4248436</ArticleId><ArticleId IdType="pubmed">25452767</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono K, Takahashi R, Ikeda T, Yamada M. Cross-seeding effects of amyloid &#x3b2;-protein and &#x3b1;-synuclein. J Neurochem. 2012;122:883&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">22734715</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones TL, Attems J, Thal DR. Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol. 2017;134:187&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5508034</ArticleId><ArticleId IdType="pubmed">28401333</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomperts SN, Marquie M, Locascio JJ, Bayer S, Johnson KA, Growdon JH. PET Radioligands reveal the basis of dementia in Parkinson's disease and dementia with Lewy bodies. Neurodegener Dis. 2016;16:118&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4838335</ArticleId><ArticleId IdType="pubmed">26655867</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RG, Lacomblez L, Landwehrmeyer BG, Bak T, Uttner I, Dubois B, Agid Y, Ludolph A, Bensimon G, Payan C, et al. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain. 2010;133:2382&#x2013;2393.</Citation><ArticleIdList><ArticleId IdType="pubmed">20576697</ArticleId></ArticleIdList></Reference><Reference><Citation>Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23:837&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">18307261</ArticleId></ArticleIdList></Reference><Reference><Citation>Postuma RB, Poewe W, Litvan I, Lewis S, Lang AE, Halliday G, Goetz CG, Chan P, Slow E, Seppi K et al (2018) Validation of the MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord: Doi. 10.1002/mds.27362</Citation><ArticleIdList><ArticleId IdType="pubmed">30145797</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkkinen L, Soininen H, Laakso M, Alafuzoff I. Alpha-synuclein pathology is highly dependent on the case selection. Neuropathol Appl Neurobiol. 2001;27:314&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">11532162</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>